Clinical Trial

Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Hot flashes present a considerable problem for many breast cancer patients; these symptoms may be intensified by hormonal therapies, such as aromatase inhibitors or tamoxifen. This study examines the value of solifenacin (a muscarinic acetylcholine receptor antagonist) in reducing hot flashes, compared with clonidine (a medication often used for treating hot flashes).
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2012-02-07; most recent amendment 2026-03-03.
Status change: Active, Not Recruiting → Recruiting 2025-04-28
Status change: Recruiting → Active, Not Recruiting 2019-03-28
Trial Details
NCT Number NCT01530373
Lead Sponsor University of Arkansas
Conditions Hot Flashes, Breast Cancer
Enrollment 110 participants
Start Date 2012-02
Primary Completion 2027-07 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-05